INTRODUCTION
Staphylococcus aureus is a commensal bacterium and a pathogen that causes a range of infections in healthcare settings and in the community, including sepsis, pneumonia, osteomyelitis, septic arthritis, bloodstream infection, and skin and soft tissue infection (SSTI) [1] . S. aureus is by far the most common cause of SSTI in the United States, and these infections represent an enormous burden, both in terms of financial and healthcare-related resources [2] . Recurrent SSTIs are common and the emergence of multidrug-resistant S. aureus isolates limits available antimicrobial therapies. A recent report documented that, among adults and children with a S. aureus SSTI in Chicago and Los Angeles, a recurrent SSTI was reported in 39% of patients within 3 months, and more than 50% within 6 months [3 & ]. The extremely high rate of recurrence in this study is concordant with other reports [4] and underscores the need to better understand the host factors that predispose to recurrent infection.
TEXT OF REVIEW
Although many risk factors for recurrent S. aureus SSTI have been identified, it is important to recognize that the vast majority of recurrent infections occur in individuals without identified risk factors. Individuals with persistent exposure to healthcare settings have a high rate of recurrent infections, which is likely due to a combination of healthcare exposure and the presence of comorbid conditions that predispose to S. aureus infections, such as diabetes mellitus, chronic renal failure requiring hemodialysis, and any condition necessitating surgical correction or palliation [5] .
Epidemiology of recurrent S. aureus skin and soft tissue infection: populations at risk
An important risk factor for recurrent infection is age; children may be particularly susceptible to recurrence. Of 95 children who were treated for a purulent SSTI at the Johns Hopkins emergency department in 2006-2007, 22% had another SSTI within 3 months. It is possible that the genetic background of the infecting isolate or the antibiogram may have had an impact on the risk of recurrence because those with an initial methicillinresistant S. aureus infection were more likely than those with a methicillin-susceptible S. aureus infection to have a recurrence (28 vs. 5%) [6] . In one retrospective study, at least 5% of children with community-associated S. aureus infections had at least one recurrence; remarkably, more than 70% of these children had no known risk factors for recurrent infection, and fewer than 5% of the infections were not an SSTI [7] . In another study, recurrent infection (primarily SSTI) occurred in 50% of children with S. aureus SSTI within 12 months, compared with 22% of children with invasive S. aureus infection [4] .
Although recurrent S. aureus SSTIs occur frequently in children, they are also common among adults. For example, recurrence rates among adults with a community-onset SSTI have been reported to be 21-50% [3 & ,8] . Populations with increased frequency of recurrent S. aureus infection include incarcerated individuals [9] , military personnel [10] , men who have sex with men [11] , and travelers to certain regions [12] . Environmental factors may also be important in recurrence; for example, recurrent infections in patients with a S. aureus SSTI were associated with contaminated household fomites and SSTI in household contacts [3 Innate and adaptive immunity against S. aureus skin and soft tissue infection: overview Many interactions of S. aureus with host immunity have been well characterized. As is the case with many pathogens, innate immunity is the first line of defense against S. aureus. Innate defenses against cutaneous S. aureus infection include the barrier function of skin, antimicrobial peptides, complement, neutrophils, macrophages, and other innate immune cells, such as gd T cells [13] . It is less well understood how (and if) the adaptive immune system reacts to S. aureus infection or colonization in order to shape memory responses that protect against recurrent infections. Adaptive immunity is traditionally classified into cell-mediated (T lymphocyte) and humoral (B lymphocyte/antibody) immunity. Vaccines against S. aureus infections have targeted humoral immunity, but the failure of several candidates despite high levels of vaccinespecific antibody among vaccinated individuals [14] demonstrates a need to better understand both the mechanisms of protective immunity and those employed by S. aureus to evade immune surveillance and defense.
Neutrophils as the first line of innate defense against primary S. aureus skin and soft tissue infection
Neutrophils have long been established as critical for defense against S. aureus SSTI. For example, chronic granulomatous disease or congenital neutropenia results in a high risk of recurrent infection [15] . Congruent with human disease, neutrophils are required for defense in a mouse model of S. aureus SSTI [16] . However, demonstrating a role for neutrophils is highly dependent on assay conditions, particularly in the presence of opsonizing antibody [17] . Moreover, the timing of the neutrophil response may be critical. For example, abrogation of integrin-mediated neutrophil crawling prior to infection worsened lesion severity in a mouse model of S. aureus SSTI, but abrogation shortly after infection improved outcomes [18 && ]. This suggests that, although neutrophils are clearly critical to control S. aureus SSTI, a sustained neutrophil response may prevent resolution of infection.
Innate defenses against S. aureus skin and soft tissue infection: other considerations
Other recent mechanistic insights into important immune pathways include the identification of the proinflammatory interleukin (IL)-1b, acting via the IL-1R and the NALP3 inflammasome, as critical for defense against S. aureus SSTI [13] . The innate gd T cells are a key source of IL-17 after S. aureus infection, and have been identified as critical in a mouse model of SSTI [13, 19 && ]. This role may be distinct from the role of IL-17 in adaptive immunity against S. aureus SSTI (discussed below Adaptive immunity against S. aureus skin and soft tissue infections: limitations of animal models
A key unanswered question is whether or not S. aureus SSTIs (or any S. aureus infections) elicit immunity that protects against recurrent infection. Because of the uncertainty resulting from clinical studies, there is an urgent need to better understand protective immunity in experimental models of S. aureus SSTI. Several mouse models of primary S. aureus SSTI in naive animals have been reported. For example, subcutaneous or epicutaneous inoculation results in dermonecrotic lesions with underlying abscess formation that resemble infections in humans [28, 29] . These models have proven invaluable for understanding the microbial determinants of virulence and innate immune responses. However, these models employ infection in mice that are immunologically naive to S. aureus, a major limitation given the nearly ubiquitous presence of antistaphylococcal antibodies in the human population.
There are other important limitations to the mouse models. First, mice are probably not a natural reservoir of S. aureus, and are believed to be resistant to the effects of superantigens, limiting our ability to understand the contributions of these important virulence factors to the pathogenesis of these infections [30] . Second, the structure of mouse skin is different from human skin [31] . Third, there are important differences between human and mouse innate and adaptive immune responses, particularly when considering the role of innate immune cells such as gd T cells [32] . However, the relatively low cost, availability, and the ability to interrogate host immune mechanisms through the use of genetically modified mice are significant advantages that must be considered.
Cell-mediated immunity
T lymphocytes are clearly important in adaptive immunity against S. aureus SSTI. For example, patients with the hyper-IgE syndrome, characterized by defects in Th17/IL-17 immunity, are at high risk for recurrent skin and pulmonary infections [33] . These observations have led many to believe that targeting the Th17/IL-17 pathway will be essential to vaccine design. Along these lines, at least one candidate vaccine in preclinical evaluation, NDV-3 (Novadigm), protects against S. aureus SSTI via IL-17A and the related T cell cytokine, IL-22 [34 & ]. However, the mechanisms underlying recurrent staphylococcal disease in hyper-IgE syndrome remain incompletely understood and are likely more complex than simply IL-17 deficiency; the immunodeficiency is actually comprised of a heterogenous collection of phenotypes caused by multiple genetic mutations [35] .
In further support of a role for T cells in defense against S. aureus SSTI, patients with poorly controlled HIV (as assessed by low CD4 þ T cell counts and high viral loads) frequently have recurrent SSTI [36] , although there are conflicting data on the importance of CD4 þ counts as a predictor of SSTI risk [37] . Patients with atopic dermatitis are also susceptible to S. aureus SSTI, which may be partly due to increased levels of Th2 cytokines and subsequent signal transducer and activator of transcription 6 (STAT6) expression that may increase susceptibility to Hla-induced keratinocyte death [38] .
A recently reported mouse model has provided experimental support for a role for T cells in protection against recurrent S. aureus SSTI. In this model, primary and secondary SSTI were separated by 8 weeks [39 & ]. Interestingly, primary SSTI protected BALB/c but not C57BL/6 mice against recurrent experimental SSTI, resulting in smaller skin lesions, a decrease in the number of bacteria recovered from the skin lesions, and attenuated local inflammation. Effector T cell mechanisms were critical, because protection occurred even in the absence of B cells and antibody, and adoptive transfer of T cells from S. aureus-infected BALB/c mice protected naive mice. Primary SSTI elicited differential T cell polarization, with a Th17/IL-17A-biased response in BALB/c mice, compared with a Th1/ IFNg-biased response in C57BL/6 mice, suggesting opposing roles for Th17 and Th1 responses in protection. Indeed, neutralization of IL-17A abrogated protection, and neutralization of IFNg enhanced protection.
In further support of a role for T cell-mediated immunity, Murphy et al. [40 & ] reported that intraperitoneal infection of mice with S. aureus elicits gd T cell-mediated protection against secondary infection. Although gd T cell-mediated protection against primary infection required IL-1 signaling, consistent with other reports documenting the importance of this cytokine in innate immune defense against S. aureus SSTI [13] , IL-1 was dispensable for expansion of the memory gd T cell population. These findings highlight the potential distinction between innate and adaptive mechanisms, and underscore the importance of investigating immune defenses in the setting of animals that have previously been exposed to S. aureus.
Antibody-mediated immunity
Whereas T cell-mediated immunity is clearly important in adaptive immunity against S. aureus, a role for antibody-mediated immunity has not been definitively established. Patients with defects in antibody-mediated immunity, such as X-linked hypogammaglobulinemia, may have increased risk of recurrent S. aureus SSTI, but this association is not entirely clear [41] . Natural antibodies against S. aureus in humans are detectable shortly after birth, but have not been demonstrated to be protective [42] . Furthermore, a substantial body of evidence suggests that infection elicits antibody responses in patients, but whether these are protective is not clear. Children with S. aureus SSTIs developed transient humoral responses that were not associated with protection against recurrent SSTI; however, invasive S. aureus infection elicited higher antibody levels against Hla, and these children had a lower risk of recurrent infection, suggesting a protective role for these antibodies [4] . Compared with healthy controls, children with invasive S. aureus infection, but not S. aureus SSTI, had higher levels of antibody against bicomponent leukotoxins, but it is not known if these are associated with protection against subsequent infection [43] . Therefore, it is clear that antistaphylococcal antibodies are common in the population, regardless of known infection history, and that these antibody repertoires are not entirely protective.
In the mouse model of recurrent SSTI discussed above, adoptive transfer of serum and purified antibody from previously infected BALB/c mice protected naive BALB/c and C57BL/6 mice against S. aureus SSTI, demonstrating a clear role for antibody-mediated immunity in this model [39 & ]. Importantly, serum from infected C57BL/6 mice did not protect mice of either genetic background, suggesting that comparison of protective BALB/c and nonprotective C57BL/6 serum might identify antigen-specific protective antibody repertoires, an important direction for future research.
Another model of reinfection has recently been reported, in which primary SSTI with 1 Â 10 7 CFU in C57BL/6 mice was followed 21 days later by secondary SSTI with 3-4 Â 10 7 CFU [44 & ]. Mice that were primarily infected with S. aureus had larger lesions after a second SSTI, compared with mice that were primarily infected with an isogenic S. aureus isolate in which Hla was deleted. There were no significant differences in the number of bacteria recovered from skin lesions 1 or 3 days after the second SSTI. Therapeutic delivery of a recombinant inactive Hla mutant or an ADAM10 inhibitor decreased the severity of secondary SSTI. These results support the hypothesis that Hla suppresses local inflammatory responses and the subsequent development of Th1 and Th17 responses [45] .
Interfering with protective antibody?
The findings that some antibody responses may protect against S. aureus SSTI are difficult to reconcile with the notion that the nearly ubiquitous antistaphylococcal antibody repertoire has not been demonstrated to be protective. One possible explanation is that only a limited antigen-specific repertoire is protective, and the majority of antistaphylococcal antibodies are not protective. It appears that S. aureus is capable of patterning the host antibody response in order to favor nonprotective responses. For example, in a small study of patients with S. aureus infection (primarily SSTI), Pauli et al. [46 && ] demonstrated that activation of B cells was limited, with a predominant bias toward those having specificity toward staphylococcal protein A (SpA), suggesting that this response limits development of antibody against other S. aureus antigens. Therefore, it is plausible that this immunodominant response prevents the development of an otherwise protective antibody repertoire.
CONCLUSION
Recurrent S. aureus SSTI is extremely common, occurring in up to half of infected patients. Environmental and epidemiologic factors are clearly associated with recurrence, as are comorbid conditions. Clinical investigations have identified innate and T cell-mediated immunity as important mechanisms of protection against recurrent infection, but the role of antistaphylococcal antibodies, which are present in nearly all sampled individuals, is less clear. It is likely that S. aureus inhibits protective antibody responses, at least partly via protein A, with a resulting antibody response that is skewed toward a nonprotective repertoire. Several recently described animal models of recurrent infection show promise, and point to multiple mechanisms of defense against recurrent SSTI requiring both antibody-mediated and T cell-mediated immunity. Additional investigation is necessary to define the nature of protective immunity elicited by S. aureus infections.
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